Clinical Trials Logo

Ulcer clinical trials

View clinical trials related to Ulcer.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06353828 Active, not recruiting - Ulcerative Colitis Clinical Trials

Phase 2a Study to Evaluate IcBD-01 Enema in Active Ulcerative Colitis Patients

Start date: March 1, 2023
Phase: Phase 2
Study type: Interventional

Ulcerative proctitis can lead to considerable morbidity, and the available treatment options are limited. Cannabidiol (CBD), a non-psychotropic ingredient of Cannabis sativa, possesses potent immunomodulatory and anti-inflammatory properties as described in both acute and chronic animal models of inflammation, including IBD models. Based on positive safety and initial efficacy profiles of CBD found in IBD animal and clinical studies, the main aim of this study is to evaluate the safety, tolerability and efficacy of a novel enema formulation of CBD for the treatment of active ulcerative proctitis.

NCT ID: NCT06221995 Active, not recruiting - Surgery Clinical Trials

Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery

Start date: September 25, 2023
Phase:
Study type: Observational

A prospective observational study to assess the energy needs of Ulcerative Colitis patients undergoing total proctocolectomy with ileoanal j-pouch anastomosis.

NCT ID: NCT06013696 Active, not recruiting - Ulcerative Colitis Clinical Trials

Bleach and Urine Color in UC Patients Using 5ASA

Asableach
Start date: July 16, 2023
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the effect on urine color by adding household bleach to fresh urine sample among pediatric UC subjects treated with 5ASA

NCT ID: NCT06003530 Active, not recruiting - Diabetic Foot Ulcer Clinical Trials

Study for Treatment of Chronic Diabetic Foot Ulcers With the Investigational Allogeneic Cell Therapy Product, hOMSC200

Start date: January 6, 2022
Phase: Phase 1
Study type: Interventional

Purpose of this phase 1/2a study is to assess the safety and efficacy of administration of allogeneic human oral mucosal stem cells (hOMSCs) in patients suffering from chronic diabetic foot ulcers (DFU).

NCT ID: NCT05931081 Active, not recruiting - Clinical trials for Chronic Ulcer of Skin

Thermal Imaging in Diagnostics of Chronic Ulcers and in Monitoring Healing of Chronic Ulcers

R22108L
Start date: March 1, 2023
Phase:
Study type: Observational [Patient Registry]

Patients with chronic ulcer needing tertiary care referred to the Wound Center of Tampere University Hospital are invited to this study. Patients are treated according to standard treatment practices. The temperature of the lower limbs and ulcer area is measured during visits using the Thermidas Remote thermal imaging system, a CE-marked medical device for measuring and monitoring changes in skin surface temperature non-invasively. The measured temperatures and differences are compared in different ulcer aetiology groups and analyzed whether thermal imaging can be used to distinguish atypical ulcers from vascular ulcers. Thermal imaging measurements and clinical examinations are repeated to the patients with atypical ulcers during follow-up visits. Monitoring of ulcers will continue until the ulcer has epithelized completely or for up to a year.

NCT ID: NCT05896943 Active, not recruiting - Ulcerative Colitis Clinical Trials

The Application of Transcriptomics in the Treatment of Ulcerative Colitis With Ustekinumab

Start date: April 1, 2022
Phase:
Study type: Observational

The investigators hope that the present study will highlight new transcriptomic prognostic markers of response to Ustekinumab with the ultimate goal of individualizing treatment and making a more targeted selection of UC patients who will benefit from this biological agent.

NCT ID: NCT05788549 Active, not recruiting - Ulcerative Colitis Clinical Trials

Assessment of the Effectiveness of Progressive Relaxation Techniques in Individuals With Ulcerative Colitis

Start date: February 1, 2022
Phase: N/A
Study type: Interventional

Ulcerative colitis is a chronic disease that follows a course of remission and flare-ups. Especially during flare-ups, the worsening of symptoms negatively affects all aspects of the individual's life and decreases their quality of life. Individuals sometimes have difficulty accessing healthcare facilities. In addition, every hospital admission causes an additional burden on healthcare institutions and the individual, both physically and financially. Therefore, it is of great importance to support and develop self-management behaviors for individuals to control their symptoms. Progressive relaxation techniques are a relaxation method based on the principle of voluntary contraction and relaxation of muscle groups in our body. It has been reported that progressive relaxation techniques, which are applied in many chronic diseases and procedures, improve symptoms and disease parameters reported by individuals, especially pain, anxiety, and stress. When the literature in the world and Turkey is examined, no study applying progressive relaxation techniques to ulcerative colitis patients has been encountered. It is known that especially stress and anxiety affect the number and severity of flare-ups in ulcerative colitis patients. It is thought that this study will contribute to the self-management behaviors of ulcerative colitis patients in the rare diseases group for the Turkish population and fill the gap in the literature.

NCT ID: NCT05764876 Active, not recruiting - Yaws Clinical Trials

Repurposing Clinically Approved Drugs for Yaws With an Insight Into the Cutaneous Ulcer Disease Syndrome (Trep-AByaws)

Trep-AByaws
Start date: March 14, 2023
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to test the non inferiority of linezolid compared with azithromycin as a treatment for yaws . The main questions it aims to answer are: can linezolid cure active yaws, and can linezolid cure latent yaws. Participants with serologically confirmed yaws will be randomized to receive linezolid (experimental) or azithromycin (control group) treatment and followed up to assess clinical resolution.

NCT ID: NCT05687643 Active, not recruiting - Diabetic Foot Ulcer Clinical Trials

Shear Load In-shoe Plantar Sensing/Strain Analyses and Mapping in Diabetic Foot Ulcers

SLIPSTREAM
Start date: July 1, 2022
Phase:
Study type: Observational

Stain Analysis Mapping of the Plantar surface (STAMP) is a method designed by the University of Leeds to measure 'in-shoe' strain patterns on the plantar surface of the foot. Shear Load Inductive Plantar Sensing (SLIPS) is an insole designed by the University of Leeds to measure plantar shear stress and plantar pressure. This study aims to compare plantar strain using STAMP and plantar shear stress and plantar pressure using SLIPS in two groups of patients with diabetes; high risk patients with a recently healed plantar ulcer and low risk patients (according to the NICE definition).

NCT ID: NCT05653791 Active, not recruiting - Ulcerative Colitis Clinical Trials

Early Intestinal Ultrasound in Predicting Treatment Response to Filgotinib in Ulcerative Colitis

STEER
Start date: October 1, 2022
Phase:
Study type: Observational

Objective disease assessment in inflammatory bowel diseases at the time of treatment initiation and during follow-up has become gold standard. However, biomarkers, such as C-reactive protein and fecal calprotectin, fail to provide information on disease extent, location or complications. Repeated endoscopic assessments are performed to evaluate mucosal response to treatment, though associated costs, availability, invasiveness and patient preference are considerable limitations. Recently, intestinal ultrasound (IUS) has gained significant momentum as a non-invasive, easily accessible and low-cost alternative for objective assessment. Accordingly, the ECCO-ESGAR guideline recognizes IUS as a potential tool for the diagnosis and for the monitoring of IBD. Our study aim is to evaluate the change in intestinal ultrasound parameters (as measured by B-mode and SWE at baseline and week 4) to predict endoscopic response and remission as defined by the follow-up endoscopy and measured by the Mayo endoscopic subscore and the UCEIS during treatment with filgotinib